Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
AssigneesUniversity of Maryland, Baltimore, The United States of America as represented by the Department of Veterans Affairs
InventorsPaul S. Shapiro, Alexander D. Mackerell, Jr., Jeffrey D. Hasday
Life of this patent
Estimating the term…
Abstract
Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.
Claims14
A method of treating an inflammatory disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound having the formula:
- wherein,
- L1 is selected from —CH2—, —C(CH3)2—, and —C(CH2CH2)—;
- and
- L4 is selected from —NHCO—, —CONH—, —SO2NH—, —NHSO2—, and —CH═CH—.
A method of treating Alzheimer's disease, psoriasis, atherosclerosis, pain, multiple sclerosis, or glomerulosclerosis in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound having the formula:
- wherein,
- L1 is selected from —CH2—, —C(CH3)2—, and —C(CH2CH2)—;
- and
- L4 is selected from —NHCO—, —CONH—, —SO2NH—, —NHSO2—, and —CH═CH—.
A method of treating cancer in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound having the formula:
- wherein,
- L1 is selected from —CH2—, —C(CH3)2—, and —C(CH2CH2)—;
- and
- L4 is selected from —NHCO—, —CONH—, —SO2NH—, —NHSO2—, and —CH═CH—.
Dependencies are inferred from the claim text.